- AstraZeneca (NYSE:AZN) upgraded to Outperform by Credit Suisse (SIX:CSGN).
- Bluebird bio (NASDAQ:BLUE) upgraded to Outperform by Evercore ISI.
- Aerie Pharmaceuticals (NASDAQ:AERI) price target raised to $76 from $65 by Needham after FDA approval of Rhopressa.
- Halozyme (NASDAQ:HALO) price target raised to $29 from $26 by Piper Jaffray.
- Johnson & Johnson (NYSE:JNJ) price target raised to $160 from $157 by Jefferies.
- ANI Pharmaceuticals (NASDAQ:ANIP) price target raised to $66 from $60 by Canaccord Genuity.
- Alkermes (NASDAQ:ALKS) downgraded to Equal Weight by Barclays (LON:BARC).
- Abiomed (NASDAQ:ABMD) downgraded to Neutral by BTIG Research.
- PhaseRx (NASDAQ:PZRX) downgraded to Neutral by Laidlaw.
- Audentes Therapeutics (NASDAQ:BOLD) downgraded to Neutral by Evercore ISI.
- Bristol-Myers Squibb (NYSE:BMY) downgraded to Hold by Jefferies.
- Trevena (NASDAQ:TRVN) downgraded to Equal Weight by Barclays.
- Now read: AstraZeneca, Time To Expand The Operation
Original article